Galway, Ireland-based Medtronic plc (MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients. Valued at $109.3 billion by market cap, the company's principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders.
Shares of this medical devices giant have underperformed the broader market over the past year. MDT has declined 3% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 21.8%. In 2026, MDT stock is down 9.8%, compared to the SPX’s 11% rise on a YTD basis.